Will resistance to Duvelisib develop?

Duvelisib (Duvelisib) is a PI3K inhibitor that brings hope of long-term survival and even cure for patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, etc. However, like other drugs, resistance to duveliside may develop. This means that over a period of time, the drug may no longer be effective because the cancer cells have found ways to bypass the drug's effects. The timing of the emergence of drug resistance may vary from person to person, but patients do not need to worry unduly. Doctors will closely monitor the patient's response to treatment and adjust the treatment plan if necessary.